Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients

Journal of Endocrinological Investigation

Volumn 21, Issue 5, 1998, Pages 310-317

  Bernini, G P ^a   Brogi, G ^a   Argenio, G F ^a   Moretti, A ^a   Salvetti, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Adrenal and testicular reserve; Pravastatin; Spermatogenesis

Indexed keywords

ALDOSTERONE; ANDROSTENEDIONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHORIONIC GONADOTROPIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TESTOSTERONE;

ALDOSTERONE BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOCRINE FUNCTION; ESTRADIOL BLOOD LEVEL; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; REPRODUCTION; SEMEN ANALYSIS; SPERMATOGENESIS; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; STEROIDOGENESIS; TESTOSTERONE BLOOD LEVEL;

EID: 0031745695     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350334     Document Type: Article

References (32)

1. Brown M.S., Kovanen P.T., Goldstein J.L. Receptor mediated uptake of lipoprotein cholesterol and its utilization for steroid synthesis in the adrenal cortex. Recent Prog. Horm. Res. 35: 215, 1979.
2. Gwynne J.T., Strauss J.F. The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic cells. Endocr. Rev. 3: 299, 1982.
3. Tureck R.W., Strauss III J.F. Progesterone synthesis by luteinized human granulosa cells in culture: the role of de novo sterol synthesis and lipoprotein-carried sterol. J. Clin. Endocrinol. Metab. 54: 367, 1982.
4. Illingworth D.R., Kenny T.A., Orwoll E.S. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J. Clin. Endocrinol. Metab. 54: 27, 1982.
5. Illingworth D.R., Lees A.M., Lees R.S. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism 30: 1045, 1983.
6. Biemer J.J., McCammon R.E. The genetic relationship of abetalipoproteinemia and hypobetalipoproteinemia: a report of occurrence of both diseases within the same family. J. Lab. Clin. Med. 85: 556, 1975.
7. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319: 24, 1988.
8. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89: 1329, 1994.
9. Tobert J.A., Bell G.D., Birtwell J., James I., Kurovetz W.R., Pryor J.S., Buntinx A., Holmes I.B., Chao Y.S., Bolognese J.A. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J. Clin. Invest. 69: 913, 1982.
10. Farnsworth W.H., Hoeg J.M., Maher M., Brittain E.H., Sherins R.J., Brewer Jr H.B. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J. Clin. Endocrinol. Metab. 65: 546, 1987.
11. Laue L., Hoeg J.M., Barnes K., Loriaux D.L., Chrousos G.P. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway. J. Clin. Endocrinol. Metab. 64: 531, 1987.
12. Jay R.H., Sturley R.H., Stirling C., Mc Garrigle H.H.G., Kats M., Reckless J.P.D., Betteridge J. Effects of pravastatin and colestiramin on gonadal and adrenal steroid production in familial hypercholesterolemia. Br. J. Clin. Pharmacol. 32: 417, 1991.
13. Mol M.J.T.M., Stanlenhoef F.H., Stuyt P.M., Hermus A.R.M.M., Demacker P.N.M., Van 'T Laar A. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin. Endocrinol. (Oxf.) 31: 679, 1989.
14. Prihoda J.S., Pappu A.S., Smith F.E., Illingworth D.R. The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia. J. Clin. Endocrinol. Metab. 72: 567, 1991.
15. Azzarito C., Boiardi L., Zini M., Agosti A., Dotti C., Biagi R., Portioli I. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients. Metabolism 41: 148, 1992.
16. Illingwoth D.R., Corbin D. The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA 82: 6291, 1985.
17. Yamaguchi K., Nakamura N., Uzawa N. Blocking 3-hydroxy-3-methyl glutaryl coenzyme A reductase with ML-236 B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia. J. Clin. Endocrinol. Metab. 58: 786, 1984.
18. Azzarito C., Boiardi L., Vergoni W., Zini M., Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm. Metab. Res. 28: 193, 1996.
19. Rossato M., Guarneri G., Lavagnini T., Padovan D., Foresta C. Simvastatin influences testicular steroidogenesis in human. Horm. Metab. Res. 25: 503, 1993.
20. Dobs A.S., Sarma P.S., Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 42: 1146, 1993.
21. Travia D., Tosi F., Negri C., Faccini G., Moghetti P., Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J. Clin. Endocrinol. Metab. 80: 836, 1995.
22. Mac Donald J.S., Gerson R.J., Kornrust D.J., Kloss M.W., Prahalada S., Berry P.H., Alberts A.W., Bokelman D.L. Preclinical evaluation of lovastatin. Am. J. Cardiol. 62: 16J, 1988.
23. Purvis K., Tollefsrud A., Rui H., Hang E., Norseth J., Viksmoen L., Ose L., Lund H. Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolemia. Eur. J. Clin. Pharmacol. 42: 61, 1992.
24. Bernini G.P., Argenio G.F., Gasperi M., Vivaldi M.S., Franchi F., Salvetti A. Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients. J. Endocrinol. Invest. 17: 227, 1994.
25. Germershansen J.I., Hunt U.M., Bostedor R.G., Bailey P.J., Karkas J.D., Alberts A.W. Tissue selectivity of the cholesterol lowering agent lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 158: 667, 1989.
26. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa K., Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3 hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochem. Biophys. Acta 1045: 1115, 1990.
27. Kuroda M., Hatsumoto A., Itakura H., Watanabe Y., Ito T., Shiomi M., Fukushige J., Nara F., Fukami M., Tsujita Y. Effects of pravastatin sodium alone and in combination with cholestiramina on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe hevitable hyperlipidemic rabbits. Jpn. J. Pharmacol. 59: 65, 1992.
28. Simpson E.R., Carr B.R., Parker C.R. Jr, Milewich L., Porter J.C., MacDonald P.C. The role of serum lipoproteins in steroidogenesis by the human fetal adrenal cortex. J Clin. Endocrinol. Metab. 49: 146, 1979.
29. Engelhard H., Gore-Langton R.E., Armstrong D.T. Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of 17 x hydroxylase: C17, 20-lyase complex. Endocrinology 124: 2297, 1989.
30. Kovanen P.T., Bilheimer D.W., Goldstein J.L., Jaramillo J.J., Brown M.S. Regulatory rate for hepatic low density lipoproteins in vivo in the dog. Proc. Natl. Acad. Sci. USA 78: 1194, 1981.
31. Gerson R.J., Mac Donald J.S., Alberts A.W., Kornhrust D.J., Majka J.A., Stubbs R.J., Bokelman D.L. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-Coenzyme A Reductase inhibitors. Am. J. Med. 87 (suppl. 4A): 28S, 1989.
32. Smals A.G.H., Weusten J.A.M., Benraad T.J., Kloppenborg P.W.C. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxydoreductase enzyme activity. J. Steroid Biochem. Mol. Biol. 38: 465, 1991.